BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. The agreement includes the issuance of 961,446... Read More

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025 BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of... Read More

BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With... Read More

BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences. Randy Milby, Chief Executive Officer, will attend the 2024 Spartan Capital Investor Conference being held on November... Read More

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting with the European Medicines Agency (EMA) that included guidance on a planned Phase 2 trial to advance TH104, the Company's lead... Read More

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile TH104 was well tolerated with no unexpected treatment-emergent adverse events, supporting further clinical development Company expects Phase 2 topline data for chronic pruritus in primary biliary cholangitis (PBC) patients in 2025 BRIDGEWATER, NJ / ACCESSWIRE / October... Read More

BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences. Nir Barak, M.D., Chief Medical Advisor, will present new results from the Company's Phase 1 trial of TH104 in a... Read More

Business combination to form a best-in-class, transformative oral biologics company Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth Merger anticipated to close in 1Q25 BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic... Read More

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α)... Read More

BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB). Prof. Jones has earned an international... Read More

BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team. "Tharimmune is pleased to have David join in an advisory capacity," stated Randy... Read More

BRIDGEWATER, NJ / ACCESSWIRE / July 16, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch of its new website at www.tharimmune.com . This redesigned online platform provides patients, healthcare professionals and stakeholders with comprehensive information about... Read More

BRIDGEWATER, NJ / ACCESSWIRE / July 10, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of Jules Haimovitz as a Strategic Advisor to the Company's executive management team. "We are pleased to have Jules join Tharimmune in an advisory capacity," stated Randy... Read More

BRIDGEWATER, NJ / ACCESSWIRE / June 20, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, developing lead candidate, TH104 for chronic pruritus in primary biliary cholangitis announced today that it has entered into a securities purchase agreement for the purchase and sale of an... Read More

FDA Provides Positive Feedback to Company Regarding TH104 Phase 2 Program Company Incorporating FDA Feedback into Phase 2 Protocol Company Believes it is On-track to Initiate Phase 2 Trial BRIDGEWATER, NJ / ACCESSWIRE / June 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports... Read More

BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego. The Company will be presenting at the convention and will hold 1x1... Read More

BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock after the close of trading on The Nasdaq Capital Market ("Nasdaq") on May 24,... Read More

BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced that management will be participating in two investor conferences in May. Randy Milby, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: VEGAS 2024 being held at... Read More

Obtained rights from Washington University to develop and incorporate human HER2 directed antibodies Complements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3 BRIDGEWATER, NJ / ACCESSWIRE / April 23, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced... Read More

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April 15, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a... Read More

Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference BRIDGEWATER, NJ / ACCESSWIRE / March 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology is pleased to announce... Read More

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studies Phase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable reference approved drug completed Company fully funded into 2025 with Phase 2 moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) study on-track and expected to initiate in 2024... Read More

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Phase 1 study expected to be completed in 1Q24 with topline readout in 2Q24 Company fully funded into 2025 with full readouts of Phase 1 and 2 in moderate-to-severe chronic pruritus in PBC expected in 4Q24/1Q25 BRIDGEWATER, NJ / ACCESSWIRE / February 5, 2024 / Tharimmune, Inc.... Read More

Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24 Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe chronic pruritus Company outlines near-clinical pipeline of novel antibody technology for multiple immuno-oncology targets and plans an R&D day in 2024 Company fully funded into... Read More

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single dose TH104 was well tolerated with no unexpected treatment-emergent adverse events comparable to previous phase 1 studies Company funded into early 2025 and expects bridging PK data in the US and Phase 2a results for chronic pruritus in primary biliary cholangitis (PBC)... Read More

BRIDGEWATER, NJ / ACCESSWIRE / November 30, 2023 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the closing of its previously announced public offering of an aggregate of 11,000,000 shares of its common stock (or pre-funded warrants ("Pre-Funded... Read More

BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each... Read More

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability Company expects to engage FDA on Phase 2 trial design and expects topline data in 2024 for chronic pruritis First indication for chronic pruritis in PBC where 70% of patients suffer from intractable... Read More

BRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announced today that it will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split was previously approved by... Read More

Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc. , (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune").... Read More

Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a... Read More

Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at... Read More

Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc. BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS)... Read More

Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors Capitalizes on “Knob” biologics (Picobodies TM ) for tumor targeting, extends partnership to include validated target, HER3 IND filing for HSB-3215 planned... Read More

Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnob TM , targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and... Read More

Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors Antibody CDRs against HER2 and HER3 Conformational Domain Bridging Epitopes can be used in multiple formats including bi- and tri-specific antibodies, antibody drug conjugates (ADCs), CAR-T and CAR-NKs BRIDGEWATER, N.J., July 06, 2023... Read More

BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell... Read More

BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the closing of its previously... Read More

12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C. BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and... Read More

BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the pricing of an underwritten... Read More

BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it intends to offer to sell... Read More

BRIDGEWATER, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, has selected immune-oncology clinical research... Read More

BRIDGEWATER, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers, announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data. These data suggest Quatramer protects HSB-1216 from metabolic... Read More

BRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, and immuno-oncology targeted novel biologics, today announced that its CEO Randy Milby will be participating – in person – at two major industry conferences in April 2023.... Read More

Management will hold 1-on-1 meetings with institutional investors and analysts Company recently signed an exclusive option agreement with Applied Biomedical Science Institute (ABSI) to license technology for HER2 and HER3 BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug... Read More

Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied Biomedical Science Institute to License... Read More

Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied Biomedical Science Institute to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian... Read More

HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against Drug Resistant Breast and Gastric Cancers Anti-HER2 and Anti-HER3 monoclonal antibodies could be effective against a number of epithelial tumors including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and... Read More

Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Lung cancer remains one of the leading causes of cancer-related deaths worldwide NSCLC accounts for approximately 80–85% of all cases of lung cancer BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE... Read More

Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ / HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor) BRIDGEWATER, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using... Read More

Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers HSB-1940, an anti-PD-1 Quatrabody™, is a proprietary targeted IO biologic BRIDGEWATER, N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug... Read More

Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC) BRIDGEWATER, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, or the “Company”), a... Read More

BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the Virtual Sidoti Micro-Cap Conference being held on January 18-19, 2023.... Read More

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940, is being developed to target PD-1 Picobodies are the smallest known antibody fragment, comprised of ultra-long CDR H3 sequences of 30-40 amino acids rich with cysteines that create tightly... Read More